...
首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.
【24h】

68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.

机译:68)Ga标记的多聚体RGD肽,用于整合素α(v)beta(3)表达的microPET成像。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: We and others have reported that (18)F- and (64)Cu-labeled arginine-glycine-aspartate (RGD) peptides allow positron emission tomography (PET) quantification of integrin alpha(v)beta(3) expression in vivo. However, clinical translation of these radiotracers is partially hindered by the necessity of cyclotron facility to produce the PET isotopes. Generator-based PET isotope (68)Ga, with a half-life of 68 min and 89% positron emission, deserves special attention because of its independence of an onsite cyclotron. The goal of this study was to investigate the feasibility of (68)Ga-labeled RGD peptides for tumor imaging. METHODS: Three cyclic RGD peptides, c(RGDyK) (RGD1), E[c(RGDyK)](2) (RGD2), and E{E[c(RGDyK)](2)}(2) (RGD4), were conjugated with macrocyclic chelator 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and labeled with (68)Ga. Integrin affinity and specificity of the peptide conjugates were assessed by cell-based receptor binding assay, and the tumor targeting efficacy of (68)Ga-labeled RGD peptides was evaluated in a subcutaneous U87MG glioblastoma xenograft model. RESULTS: U87MG cell-based receptor binding assay using (125)I-echistatin as radioligand showed that integrin affinity followed the order of NOTA-RGD4 > NOTA-RGD2 > NOTA-RGD1. All three NOTA conjugates allowed nearly quantitative (68)Ga-labeling within 10 min (12-17 MBqmol). Quantitative microPET imaging studies showed that (68)Ga-NOTA-RGD4 had the highest tumor uptake but also prominent activity accumulation in the kidneys. (68)Ga-NOTA-RGD2 had higher tumor uptake (e.g., 2.8 +/- 0.1%ID/g at 1 h postinjection) and similar pharmacokinetics (4.4 +/- 0.4 tumor/muscle ratio, 2.0 +/- 0.1 tumor/liver ratio, and 1.1 +/- 0.1 tumor/kidney ratio) compared with (68)Ga-NOTA-RGD1. CONCLUSIONS: The dimeric RGD peptide tracer (68)Ga-NOTA-RGD2 with good tumor uptake and favorable pharmacokinetics warrants further investigation for potential clinical translation to image integrin alpha(v)beta(3).
机译:目的:我们和其他人已报告(18)F-和(64)Cu标记的精氨酸-甘氨酸-天冬氨酸(RGD)肽允许在体内进行整联蛋白alpha(v)beta(3)表达的正电子发射断层扫描(PET)定量。但是,这些回旋示踪剂的临床翻译部分受到回旋加速器生产PET同位素的必要性的阻碍。基于发生器的PET同位素(68)Ga的半衰期为68分钟,正电子发射率为89%,由于其在现场回旋加速器的独立性,因此值得特别关注。这项研究的目的是研究(68)Ga标记的RGD肽在肿瘤成像中的可行性。方法:三种环状RGD肽,c(RGDyK)(RGD1),E [c(RGDyK)](2)(RGD2)和E {E [c(RGDyK)](2)}(2)(RGD4),将其与大环螯合剂1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA)偶联并标记(68)Ga。通过基于细胞的受体结合测定法评估肽缀合物的整联蛋白亲和力和特异性,并在皮下U87MG胶质母细胞瘤异种移植模型中评估(68)Ga标记的RGD肽的肿瘤靶向功效。结果:使用(125)I-echistatin作为放射性配体的基于U87MG细胞的受体结合试验显示整联蛋白亲和力遵循NOTA-RGD4> NOTA-RGD2> NOTA-RGD1的顺序。所有三种NOTA共轭物均允许在10分钟内(12-17 MBq / nmol)进行几乎定量的(68)Ga标记。定量的microPET成像研究显示(68)Ga-NOTA-RGD4具有最高的肿瘤吸收率,但在肾脏中的活动性积累也很明显。 (68)Ga-NOTA-RGD2具有更高的肿瘤吸收率(例如,注射后1 h时为2.8 +/- 0.1%ID / g)和相似的药代动力学(4.4 +/- 0.4肿瘤/肌肉比,2.0 +/- 0.1肿瘤/与(68)Ga-NOTA-RGD1相比,肝脏比率和1.1 / 0.1肿瘤/肾脏比率)。结论:具有良好的肿瘤吸收和良好的药代动力学的二聚体RGD肽示踪剂(68)Ga-NOTA-RGD2值得进一步研究,以潜在的临床翻译成图像整合素alpha(v)beta(3)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号